keyword
MENU ▼
Read by QxMD icon Read
search

osimertinib

keyword
https://www.readbyqxmd.com/read/29673089/non-small-cell-lung-cancer-harboring-a-rare-egfr-l747p-mutation-showing-intrinsic-resistance-to-both-gefitinib-and-osimertinib-azd9291-a-case-report
#1
Jing Huang, Yiyin Wang, Yachao Zhai, Jin Wang
The most common EGFR mutations in non-small cell lung cancer are exon 19 deletions and exon 21 point mutations, which are both sensitive to EGFR-tyrosine kinase inhibitors. However, rare EGFR mutations do exist and how these mutations respond to tyrosine kinase inhibitors is not well understood. A Chinese woman diagnosed with stage IV lung adenocarcinoma harbored a rare EGFR L747P (2239-2240 TT > CC) mutation, and treatment with gefitinib and osimertinib failed to achieve the desired effect. Herein, possible correlations between gene analysis and the outcomes of subsequent treatment are discussed...
April 19, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29660496/quantitative-targeted-proteomic-analysis-of-potential-markers-of-tyrosine-kinase-inhibitor-tki-sensitivity-in-egfr-mutated-lung-adenocarcinoma
#2
Shivangi Awasthi, Tapan Maity, Benjamin L Oyler, Yue Qi, Xu Zhang, David R Goodlett, Udayan Guha
Lung cancer causes the highest mortality among all cancers. Patients harboring kinase domain mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors (TKIs), however, acquired resistance always develops. Moreover, 30-40% of patients with EGFR mutations exhibit primary resistance. Hence, there is an unmet need for additional biomarkers of TKI sensitivity that complement EGFR mutation testing and predict treatment response. We previously identified phosphopeptides whose phosphorylation is inhibited upon treatment with EGFR TKIs, erlotinib and afatinib in TKI sensitive cells, but not in resistant cells...
April 13, 2018: Journal of Proteomics
https://www.readbyqxmd.com/read/29650685/osimertinib-a-novel-dermatologic-adverse-event-profile-in-patients-with-lung-cancer
#3
Chia-Yu Chu, Jennifer Choi, Beth Eaby-Sandy, Corey J Langer, Mario E Lacouture
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29650684/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-for-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#4
REVIEW
Manmeet S Ahluwalia, Kevin Becker, Benjamin P Levy
Central nervous system (CNS) metastases are a common complication in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), resulting in a poor prognosis and limited treatment options. Treatment of CNS metastases requires a multidisciplinary approach, and the optimal treatment options and sequence of therapies are yet to be established. Many systemic therapies have poor efficacy in the CNS due to the challenges of crossing the blood-brain barrier (BBB), creating a major unmet need for the development of agents with good BBB-penetrating biopharmaceutical properties...
April 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29618075/thoracoscopic-rebiopsy-to-detect-the-t790m-mutation-after-postoperative-recurrence
#5
Masatsugu Hamaji, Hideki Motoyama, Toshi Menju, Toyofumi-Fengshi Chen-Yoshikawa, Makoto Sonobe, Young Hak Kim, Hiroshi Date
After pulmonary resection for non-small-cell lung cancer, some patients with postoperative recurrence and mutated epidermal growth factor receptor (EGFR) subsequently receive EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Osimertinib may be efficacious if those patients become resistant to the 1st-line EGFR-TKI because of the T790M mutation. We recently performed thoracoscopic rebiopsy to detect the T790M mutation in 4 patients who became resistant to the 1st-line EGFR-TKI treatment for postoperative recurrence...
April 2, 2018: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29611548/osimertinib-the-winner-but-cannot-yet-take-it-all
#6
EDITORIAL
Shinkyo Yoon, Jihoon Kang, Dae Ho Lee
No abstract text is available yet for this article.
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29611546/osimertinib-in-first-line-treatment-is-a-comparison-not-proof
#7
EDITORIAL
Jacques Cadranel
No abstract text is available yet for this article.
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29610752/first-line-osimertinib-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer
#8
EDITORIAL
Byeong-Ho Jeong, Sang-Won Um
No abstract text is available yet for this article.
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29596911/concurrent-acquired-braf-v600e-mutation-and-met-amplification-as-resistance-mechanism-of-first-line-osimertinib-treatment-in-nsclc-egfr-mutated-patient
#9
Roberta Minari, Paola Bordi, Silvia La Monica, Anna Squadrilli, Alessandro Leonetti, Lorena Bottarelli, Cinzia Azzoni, Constanza Anna Maria Lagrasta, Lelizia Gnetti, Nicoletta Campanini, Pier Giorgio Petronini, Roberta Alfieri, Marcello Tiseo
No abstract text is available yet for this article.
March 26, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29594878/acquired-resistance-to-an-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-egfr-tki-in-an-uncommon-g719s-egfr-mutation
#10
Atsushi Osoegawa, Takafumi Hashimoto, Yohei Takumi, Miyuki Abe, Tomonori Yamada, Ryoji Kobayashi, Michiyo Miyawaki, Hideya Takeuchi, Tatsuro Okamoto, Kenji Sugio
Background Acquired resistance (AR) to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is a common event, and several underlying mechanisms, including T790 M, MET amplification and PTEN downregulation, have been reported for the common EGFR mutations. EGFR G719X is an uncommon mutation that has been reported to show sensitivity to EGFR-TKIs. However, no established cell lines harboring the EGFR G719X have been reported in the literature. Materials and Methods G719S-GR cells were established from malignant pleural effusion of a patient whose tumor developed AR from gefitinib treatment...
March 28, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29575765/combination-therapy-of-apatinib-with-icotinib-for-primary-acquired-icotinib-resistance-in-patients-with-advanced-pulmonary-adenocarcinoma-with-egfr-mutation
#11
Pinghui Xia, Jinlin Cao, Xiayi Lv, Luming Wang, Wang Lv, Jian Hu
Multi-targeted agents represent the next generation of targeted therapies for solid tumors, and patients with acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) may also benefit from their combination with TKI therapy. Third-generation targeted drugs, such as osimertinib, are very expensive, thus a more economical solution is required. The aim of this study was to explore the use of apatinib combined with icotinib therapy for primary acquired resistance to icotinib in three patients with advanced pulmonary adenocarcinoma with EGFR mutations...
March 24, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29571987/clinical-analysis-by-next-generation-sequencing-for-nsclc-patients-with-met-amplification-resistant-to-osimertinib
#12
Yubo Wang, Li Li, Rui Han, Lin Jiao, Jie Zheng, Yong He
INTRODUCTION: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as MET amplification. However, cohort studies of osimertinib resistance mechanism, and the correlation of MET and progression-free survival (PFS) after osimertinib resistance have been poorly investigated. OBJECTIVES: This study was carried out to study the acquired MET amplification after osimertinib resistance in advanced lung adenocarcinoma patients, and interrogate the correlation of clinical prognosis and MET amplification...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29571986/acquired-egfr-l718v-mutation-mediates-resistance-to-osimertinib-in-non-small-cell-lung-cancer-but-retains-sensitivity-to-afatinib
#13
Yutao Liu, Yan Li, Qiuxiang Ou, Xue Wu, Xiaonan Wang, Yang W Shao, Jianming Ying
OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) patients. However, acquired resistance inevitably develops. Comprehensive and dynamic companion genomic diagnosis can gain insights into underlying resistance mechanisms, thereby help oncologists and patients to make informed decision on the potential benefit of the treatment. MATERIALS AND METHODS: A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29567575/comparative-studies-on-the-human-serum-albumin-binding-of-the-clinically-approved-egfr-inhibitors-gefitinib-erlotinib-afatinib-osimertinib-and-the-investigational-inhibitor-kp2187
#14
Orsolya Dömötör, Karla Pelivan, Attila Borics, Bernhard K Keppler, Christian R Kowol, Éva A Enyedy
Binding interactions between human serum albumin (HSA) and four approved epidermal growth factor receptor (EGFR) inhibitors gefitinib (GEF), erlotinib (ERL), afatinib (AFA), osimertinib (OSI), as well as the experimental drug KP2187, were investigated by means of spectrofluorometric and molecular modelling methods. Steady-state and time resolved spectrofluorometric techniques were carried out, including direct quenching of protein fluorescence and site marker displacement measurements. Proton dissociation processes and solvent dependent fluorescence properties were investigated as well...
March 11, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29562902/effective-osimertinib-treatment-in-a-patient-with-discordant-t790-m-mutation-detection-between-liquid-biopsy-and-tissue-biopsy
#15
Isa Mambetsariev, Lalit Vora, Kim Wai Yu, Ravi Salgia
BACKGROUND: We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between liquid biopsy and tissue biopsy methods. CASE PRESENTATION: A 57-year-old Hispanic male patient initially diagnosed with an EGFR 19 deletion positive lung adenocarcinoma and clinically responded to initial erlotinib treatment...
March 21, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29555874/reactivation-of-mutant-egfr-degradation-through-clathrin-inhibition-overcomes-resistance-to-egfr-tyrosine-kinase-inhibitors
#16
Ludovic Ménard, Nicolas Floc'h, Matthew J Martin, Darren Ae Cross
Tyrosine kinase inhibitors (TKIs) targeting mutant-EGFR in NSCLC have been successful to control cancer growth, but acquired resistance inevitably occurs, including mutations directly on EGFR e.g. T790M and C797S. Strategies to prevent such acquired mutations by reducing mutant-EGFR expression have met limited success. Here we propose a new model of mutant-EGFR trafficking and demonstrate that clathrin inhibition induces rapid degradation across a large panel of endogenous mutant-EGFR (Ex19del, L858R, Ex20Ins)...
March 19, 2018: Cancer Research
https://www.readbyqxmd.com/read/29526823/antitumor-efficacy-of-dual-blockade-of-egfr-signaling-by-osimertinib-in-combination-with-selumetinib-or-cetuximab-in-activated-egfr-human-nsclc-tumor-models
#17
Carminia Maria Della Corte, Vincenza Ciaramella, Claudia Cardone, Silvia La Monica, Roberta Alfieri, Pier Giorgio Petronini, Umberto Malapelle, Elena Vigliar, Francesco Pepe, Giancarlo Troncone, Maria Domenica Castellone, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Floriana Morgillo
HYPOTHESIS: Osimertinib showed great clinical efficacy for activated-EGFR-NSCLC patients treatment. The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody, cetuximab, or the MEK1/2-inhibitor, selumetinib, in EGFR-mutated-NSCLC in vivo models. METHODS: We evaluated combinations of osimertinib plus selumetinib/cetuximab in HCC827 (E746-A759del/T790M-), H1975 (L858R/T790M+) and PC9-T790M (E746-A759del /T790M+) xenografts, in second-line after the developing of resistance to osimertinib and in first-line, and we explored mechanisms of resistance to these treatments...
March 8, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29524556/primary-and-acquired-egfr-t790m-mutant-nsclc-patients-identified-by-routine-mutation-testing-show-different-characteristics-but-may-both-respond-to-osimertinib-treatment
#18
Weihua Li, Tian Qiu, Lei Guo, Yun Ling, Yibo Gao, Jianming Ying, Jie He
Primary EGFR T790M mutation is occasionally identified by routine mutation testing in tyrosine kinase inhibitor (TKI)-naive patients with non-small cell lung cancer (NSCLC). We herein aimed to compare the characteristics of primary and acquired T790M mutations in NSCLC patients, and their response to osimertinib. Using amplification refractory mutation system (ARMS) detection, primary T790M was identified in 0.5% (46/8723) of TKI-naive patients, whereas acquired T790M was detected in 49.7% (71/143) of TKI-relapsed patients...
March 7, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29508939/case-sharing-of-a-patient-re-challenged-with-afatinib-for-egfr-mutated-advanced-non-small-cell-lung-cancer
#19
Victor H F Lee
A 65-year-old female with diabetes mellitus but otherwise good health in the past suffered from cough with occasional blood-stained sputum during initial presentation. The patient was diagnosed with pulmonary poorly differentiated adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 19 deletion and hence received afatinib therapy for 25 months without obvious adverse events except for a grade 1-2 acneiform rash. The disease was stabilized after subsequent cycles of chemotherapy with pemetrexed and carboplatin followed by maintenance pemetrexed...
March 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29506987/investigating-novel-resistance-mechanisms-to-third-generation-egfr-tyrosine-kinase-inhibitor-osimertinib-in-non-small-cell-lung-cancer-patients
#20
Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang W Shao, Yunpeng Liu, Yan Wang, Caicun Zhou
BACKGROUND:  The third generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat EGFR T790M-positive non-small cell lung cancer (NSCLC) patients who have developed resistance to earlier generation drugs. Acquired EGFR C797S mutation has been reported to mediate osimertinib-resistance in some patients. However, the remaining resistance mechanisms are largely unknown. METHODS: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNA), and matched pre-treatment samples of 12 patients...
March 5, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
95854
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"